Receptos, Inc.

Located strategically in US innovation hubs, meanwhile stationing most of their development and regulatory personnel in central cities in China, dual-headquartered China-US biotechs have been riding h

Located strategically in hubs of innovation in the US, meanwhile stationing most of their development and regulatory personnel in central cities in China, dual-headquartered China-US biotechs have bee

ImmPACT Bio USA emerged from the FutuRx incubator in Israel in 2017 to develop chimeric antigen receptor T-cell (CAR-T) therapies that could be effective against solid tumors. Now, with $111m in seri

With the US government reopened, the traditional path to an initial public offering is as well and biopharmaceutical companies are racing down that road as fast as they can in case the temporary end t